In this ASH Special Edition expert faculty provide concise, informative presentations of their practice impacting data in Myeloproliferative Neoplasms (MPNs) presented at the 61st ASH Annual Meeting in Orlando, FL. Speaker provided slides and posters are available for download.Release Date: 12/13/2019Expiration Date: 12/13/2020Estimated time to complete activity: 1.0 Hour
When you give to what you love, you have a direct impact on our more than 3,360 students. Make your mark and give to what…
Aaron Gerds, MD, is the deputy director for clinical research at Cleveland Clinic Taussig Cancer Institute and associate professor at Cleveland Clinic Lerner College of…
Approximately 50 – 60% of patients with melanoma have BRAF-activating tumors, meaning they are amenable to treatment with combination BRAF/MEK inhibitors. However, immunotherapy is also…
Advances in Precision Oncology for Blood CancersTuesdays 6th, 13th and 20th June at 3 pm BST/4 pm CET/10 am ESTCancer has emerged as the most…
MPN Hub Symposium: NCT03194542 trial: Luspatercept for the treatment of patients with anemic myelofibrosis
AuthorsAaron Thomas GerdsCleveland Clinic, Cleveland, OHAaron Thomas Gerds, Claire Harrison, Jean-Jacques Kiladjian, Ruben A. Mesa, Alessandro M. Vannucchi, Rami S. Komrokji, Prithviraj Bose, Marina Kremyanskaya,…
The goal of treatment for most patients with myelofibrosis is to relieve symptoms. A provider will use a formula to assign a risk category (indicating…
Join MPN Advocacy & Education International for an upcoming MPN patient and caregiver program in Cleveland, OH. Dr. Aaron Gerds has invited our organization to…
The FDA noted that additional requirements are needed prior to the approval of ruxolitinib extended-release for patients with myelofibrosis, polycythemia vera, and graft-versus-host disease, in…
